Netherlands-based pharma ingredients manufacturer DSM today opened it's first Purimox manufacturing facility in India with a capacity of 5,000 tonnes per annum."The plant would have an initial capacity of 2,000 tonnes per annum which would be subsequently increased to 5,000 tonnes per annum," N V Ramanan, VP (anti-infectives) of DSM, said here.However, he refused to comment on the time-frame required by the company to achieve the enhanced capacity.The company would manufacture penicillin-based antibiotic Purimox in the facility, which is used in the treatment of various infections. The facility would primarily cater to the Asia Pacific, Middle-East and African markets."We have been selling Purimox in India since 2003 and have received great response for the product in this market. The facility would not only cater to the Indian market but to the Asia Pacific, Middle-East and African region also," Gerard De Reuver, president (anti-infectives) of DSM, said. The company has a Purimox manufacturing facility in Spain with an installed capacity of 2,500 tonnes per annum, he said.When asked about the company's future plans for India, Ramanan said, "we are currently doing a market study in India which would be complete by the end of this calendar year and a decision on expansion would only be taken after the completion of this study."The market for Purimox in India is currently worth $100 million, he said.
